TheraPanacea, an award-winning French med-tech company founded in 2017, announced today it has signed an exclusive distribution agreement with OSL, Oncology Systems Limited, for UK and Ireland.
15th April 2021
“OSL is an experienced distributor of radiotherapy equipment with more than 75 customers in the UK and Ireland. So, we are excited that OSL has decided to work with TheraPanacea exclusively entering the markets in UK & Ireland. The combination of OSL’s experience and customer commitment with the cutting-edge technology of TheraPanacea’s AI-driven solutions for radiation therapy will enable customers in UK & Ireland to access the latest high-performing data-driven solutions in radio-oncology treatment to better treat their patients and streamline their clinical operations.” says Professor Nikos Paragios, CEO of TheraPanacea.
To overcome these challenges, TheraPanacea has developed an artificial intelligence (AI) guided software, ART-Plan™ for radiotherapy planning. ART-Plan™ uses Deep Learning, a form of AI technology, to fully speed up and standardize the contouring of organs at risk and lymph nodes as well as to enable high-precision rigid and elastic fusion for faster replanning. By combining the power of AI with the collective intelligence of worldwide experts, ART-Plan™ automatically generates clinically acceptable contours for all anatomies (80+ OARs) in a few minutes instead of hours of human time.
ART-Plan™ is already used in the clinical workflow of more than 40 leading European centres, which are already benefiting from exceptional time savings, optimized human resources, and standardized treatment planning workflow. Users in Europe have reported saving up to 90% of the time required for these tasks.
About OSL: Since 1999, OSL has continuously grown to become a major and trusted independent provider of medical equipment and software to the NHS and private hospitals in the UK, Ireland and worldwide. The OSL team comprises of clinically and scientifically qualified radiation therapists, medical physicists, and imaging scientists, giving OSL the expertise to manufacture and distribute state-of-the-art radiotherapy equipment from thermoplastic and positioning accessories, to advanced 4D simulation and Monte Carlo planning software, advanced targeted image fusion technology for prostate biopsy, brachytherapy and external beam treatment delivery, and medical physics devices for dosimetry and QA of external beam and proton therapy.
About TheraPanacea: A medical technology company created in 2017, TheraPanacea develops disruptive software solutions for smarter cancer prognosis and treatment. TheraPanacea’s first software for radiotherapy, ART-Plan ™, has been available on the European market since 2019. Since its creation, TheraPanacea has won prestigious distinctions and prizes including the European Research Council (ERC) Proof of Concept Grant (2016), the Digital Innovation Competition (BPI), the Grands Prix d’Innovation de la Ville de Paris in Health category (2017), the 1st AI Challenge prize for the Paris region (2018) and the H2020 – SME Instrument Phase 2 prize (2019) rewarding the most disruptive European companies in their market.
About ART-Plan™: The aim of radiotherapy is to increase the dose delivered to the tumour whilst minimizing surrounding organ damage. during radiotherapy planning, clinical staff need to identify and accurately delineate tumours as well as organs at risk. If organs are not properly delineated, the radiation plan may not protect these critical structures or adequately treat the tumour, leading to increased toxicity and potentially poorer outcomes for patients. Most of this important task is performed in a manual manner, which is not only highly time-consuming but also subject to expert variability and experience.